Major pharmaceutical companies including AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim have announced a cap of $35 on inhaler costs in the U.S. following investigations and pressure from lawmakers like Senators Sanders and Baldwin. This move aims to make inhalers more affordable for millions of Americans, addressing concerns over high prices and price gouging tactics.
For Wisconsinites like Vicki, a $35/month cap on inhalers will save them hundreds of dollars and ensure that the medication they need to stay alive will be within reach. https://t.co/z10RL7A1hh
Following a HELP Committee investigation into the outrageous prices Americans pay for inhalers, 3 of the 4 major inhaler companies made a commitment to cap the cost of all of their brand name inhalers at $35. https://t.co/XK0emmSGND
Capping inhaler costs at $35/month could be all the difference for families struggling to afford the health care they need. I’ll call out price gouging wherever it exists because Americans shouldn’t be ripped off just to get their lifesaving medications. https://t.co/jG5SZGh9TA
U.K.-based pharma giant AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker announced. https://t.co/dfnG4qUF97
Today, I am pleased to announce that, following the HELP Committee’s investigation into the outrageous prices Americans pay for inhalers, 3 of the 4 major inhaler companies made a commitment to cap the cost of all of their brand name inhalers at $35. https://t.co/UeNewOtcJB
Thanks to the work of @HELPCmteDems, 3 of the top inhaler makers have announced $35 caps on inhalers. Millions of Americans, and thousands of New Mexicans will pay far less for their inhalers. This means that people won’t have to worry about whether they can afford to breathe. https://t.co/tsraPqlpKr
Huge news: GlaxoSmithKline and AstraZeneca have agreed to cap inhalers at $35. Americans shouldn’t be paying $300 for inhalers that are only $20 in the UK. Thanks to @SenSanders and healthcare advocates, this lifesaving device is more affordable. https://t.co/YVIjBfhaV3
Big inhaler companies are raking in billions of dollars while Wisconsinites are being forced to ration their inhalers just so they can afford them. We took on these drug companies & months later, they capped their inhalers at $35/month. This is the power of transparency. https://t.co/9l5bAbvyO1
In the Senate, where @BernieSanders + colleagues are trumpeting success in lowering price of inhalers for Americans, following their investigation. Same inhalers cost 10x in US vs cost abroad. @SenatorLujan, @SenatorBaldwin, @SenTinaSmith, @SenMarkey joining Sanders on podium. https://t.co/Dp447Rj4zB
Earlier this year, the HELP Committee launched an investigation into the outrageous prices of inhalers in the U.S. Today, I’m proud to announce that 3 of the 4 major inhaler companies will lower the cost of all of their inhalers to $35. https://t.co/RInxutJC79
We launched an investigation into big drug companies jacking up inhaler costs. Within weeks, three out of the four of them came clean and capped their costs at $35/month. I will not stop fighting to lower health care costs and keep Wisconsinites healthy. https://t.co/oXKN3BHXzM
GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per month https://t.co/rP1tmxdRrj
I’m glad to see major drug companies cap their inhaler prices to $35/month after my investigation into their price-gouging tactics. I’ll take on anyone to lower health care costs for Wisconsinites. https://t.co/8tkZpgAV4r
1. Last year @FTC challenged a set of @GSK inhaler patents as improperly listed. @GSK delisted the majority of the challenged patents. Now @GSK has agreed to cap patients' out-of-pocket costs for its inhalers, from hundreds of dollars down to $35. https://t.co/gFXEPn9xXt
First it was Boehringer. Now drugmaker AstraZeneca has followed suit by capping out-of-pocket costs for inhalers to $35/mo. That’s down from over $600. But this doesn’t happen by itself. It took pressure by lawmakers like Sen. Bernie Sanders and from engaged consumer activists.
GSK to cap out-of-pocket inhaler costs in US https://t.co/sqNQJCXq7D https://t.co/Fp6UnokH3s
Following our investigation into the outrageously high cost of inhalers, the 3 largest inhaler companies – GlaxoSmithKline, Boehringer Ingelheim & AstraZeneca – will cap the cost of inhalers at $35. Millions of Americans will soon be able to afford the inhalers they need. https://t.co/2Dl0ELCr2E
Earlier this year, I called on 6 big pharmaceutical companies to stop anticompetitive practices that keep asthma inhaler prices high. Now, @AstraZeneca is the second company to cap patients' out-of-pocket costs for its inhalers at $35. Let's keep this momentum going! https://t.co/TL5eUS7T6S
Folks with asthma or COPD should not suffer because they can’t afford an inhaler. After a @HELPCmteDems investigation on the high cost of inhalers, @AstraZeneca @boehringerus both announced $35 caps on inhalers starting June 1. This is really good news.